ZIOPHARM Oncology, Inc.
ZIOP, a biopharmaceutical company focused on the development and
commercialization of new cancer therapies, announced today the presentation of
results from a study in a breast cancer murine model demonstrating the
anti-tumor effects and tolerability of Ad-RTS-mIL-12, a viral vector DNA-based
therapeutic for the controlled, local expression of IL-12, an important
protein for enhancing antitumor immunity. The data were presented at the
American Association for Cancer Research 2013 Annual Meeting (AACR 2013)
taking place April 6-10, 2013 in Washington, D.C. The study was conducted
jointly by ZIOPHARM and Intrexon Corporation, a synthetic biology company that
utilizes its proprietary technologies to provide control over cellular
function. ZIOPHARM is Intrexon's exclusive channel partner for the development
of in vivo therapeutics in oncology.
For the study, intratumoral administration of Ad-RTS-mIL-12 (Ad) was examined
in a 4T1 BALB/c mouse breast carcinoma model. Production of murine IL-12 was
controlled using Intrexon's RheoSwitch Therapeutic System^® (RTS^®) platform
and oral administration of the activator ligand INXN-1001 (AL). Oral
administration of AL was found to elicit a dose-related increase in plasma AL
levels, which correlated with increasing tumor levels of AL. The increase in
tumor AL levels in combination with Ad in turn resulted in a dose-related
increase in expression of mIL-12 in the tumor, with minimal increase in serum
mIL-12. This increase in AL-regulated tumor IL-12 levels correlated with an
increase in tumor-infiltrating CD4^+ and CD8^+ T cells in and adjacent to the
tumor, concomitant with a decrease in tumor regulatory T cells. This resulted
in a dose-related decrease in tumor growth rate. Moreover, the therapeutic
strategy appears to be well tolerated, as no change in clinical signs or body
weight was observed in the treated animals when compared with vehicle alone.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in